Studies that reported the incidence of M-protein in patients with MZL
| Study . | MZL subtype . | Sample size (N) . | Prevalence of M-protein at diagnosis N (%) . | Key observations . |
|---|---|---|---|---|
| Berger et al16 | All | 124 | 19 (15) | IgM = 15, IgG = 1, and IgA = 3 The median level of the M-protein was 8 g/L (1-51 g/L). |
| Thieblemont et al17 | SMZL | 81∗ | 34 (46) | IgM = 21, IgG = 7, and IgA = 3 Median (range) 6.5 (1-51) g/L The presence of an M-protein was significantly associated with a shorter TTP |
| Parry-Jones et al18 | SMZL | 107 | 24 (22) | IgM = 15, IgG = 8, and IgA = 1 50% had <10 g/L and the highest was 25 g/L |
| Wohrer et al19 | MALT/EMZL | 52 | 19 (36) | IgM = 10, IgG = 6, and IgA = 3 M-protein levels declined significantly in patients responding to chemotherapy or radiation |
| Arcaini et al14 | SMZL | 309 | 25 (8) | IgM = 19, IgG = 4, IgG/IgM = 1, and IgA = 1 Median 1 g/dL No prognostic relevance of M-protein for cause-specific survival in SMZL |
| Arcaini et al11 | MALT/EMZL | 208 | 36 (17) | IgM = 24, IgG = 9, and IgA = 3 The presence of M-protein correlated with advanced disease and shorter OS in MVA. |
| Troch et al24 | MALT/EMZL | 94 | 37 (39) | Did not report the breakdown of M-protein or prognostic relevance |
| Montalban et al9 | SMZL | 501 | 127 (25) | No prognostic relevance of M-protein for lymphoma-specific survival in SMZL |
| Desai et al25 | POAML | 58† | 12 (21) | IgM = 6, IgG = 4, and IgA = 2 |
| Alderuccio et al12 | MALT/EMZL | 328 | 35 (11) | IgM = 13, IgG = 15, IgA = 5, IgM/IgG = 1, and lambda LC = 1 The presence of M-protein was associated with shorter survival on univariate analysis |
| Bonfiglio et al10 | SMZL | 303‡ | 61 (20) | IgM = 39, IgG = 21, and missing = 1 No difference in M-protein between genomic subtypes of SMZL |
| Ren et al26 | MALT/EMZL | 218 | 42 (19) | IgM = 27, IgG = 5, IgA = 4, IgM/IgA = 3, IgM/IgG = 1, IgM/LC = 1, and LC = 1 M-protein was an independent prognostic factor for both PFS and OS in the multivariable analysis |
| Study . | MZL subtype . | Sample size (N) . | Prevalence of M-protein at diagnosis N (%) . | Key observations . |
|---|---|---|---|---|
| Berger et al16 | All | 124 | 19 (15) | IgM = 15, IgG = 1, and IgA = 3 The median level of the M-protein was 8 g/L (1-51 g/L). |
| Thieblemont et al17 | SMZL | 81∗ | 34 (46) | IgM = 21, IgG = 7, and IgA = 3 Median (range) 6.5 (1-51) g/L The presence of an M-protein was significantly associated with a shorter TTP |
| Parry-Jones et al18 | SMZL | 107 | 24 (22) | IgM = 15, IgG = 8, and IgA = 1 50% had <10 g/L and the highest was 25 g/L |
| Wohrer et al19 | MALT/EMZL | 52 | 19 (36) | IgM = 10, IgG = 6, and IgA = 3 M-protein levels declined significantly in patients responding to chemotherapy or radiation |
| Arcaini et al14 | SMZL | 309 | 25 (8) | IgM = 19, IgG = 4, IgG/IgM = 1, and IgA = 1 Median 1 g/dL No prognostic relevance of M-protein for cause-specific survival in SMZL |
| Arcaini et al11 | MALT/EMZL | 208 | 36 (17) | IgM = 24, IgG = 9, and IgA = 3 The presence of M-protein correlated with advanced disease and shorter OS in MVA. |
| Troch et al24 | MALT/EMZL | 94 | 37 (39) | Did not report the breakdown of M-protein or prognostic relevance |
| Montalban et al9 | SMZL | 501 | 127 (25) | No prognostic relevance of M-protein for lymphoma-specific survival in SMZL |
| Desai et al25 | POAML | 58† | 12 (21) | IgM = 6, IgG = 4, and IgA = 2 |
| Alderuccio et al12 | MALT/EMZL | 328 | 35 (11) | IgM = 13, IgG = 15, IgA = 5, IgM/IgG = 1, and lambda LC = 1 The presence of M-protein was associated with shorter survival on univariate analysis |
| Bonfiglio et al10 | SMZL | 303‡ | 61 (20) | IgM = 39, IgG = 21, and missing = 1 No difference in M-protein between genomic subtypes of SMZL |
| Ren et al26 | MALT/EMZL | 218 | 42 (19) | IgM = 27, IgG = 5, IgA = 4, IgM/IgA = 3, IgM/IgG = 1, IgM/LC = 1, and LC = 1 M-protein was an independent prognostic factor for both PFS and OS in the multivariable analysis |
Only those with ≥10 cases of M-protein are shown.
LC, light chains; POAML, primary ocular adnexal MALT lymphoma.
Seven had missing information on monoclonal protein at diagnosis.
Among the 182 patients with POAML, 58 patients underwent blood examination for the presence of monoclonal gammopathy.
Monoclonal protein was missing in 104 patients.